Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Mustufa Jafry

MOHS-Micrographic Surgery Mill Creek, WA Medical Doctor

NPI 1447888540 CMS profile 7731172

15906 Mill Creek Blvd Ste 105, Mill Creek, WA 98012

Open in the dashboard

General payments

$4,293

63 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mustufa Jafry of Mill Creek, WA is reported in the CMS Open Payments database as having received $4,293 across 63 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 71st percentile of MOHS-Micrographic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,730 34
2024 General $1,657 21
2023 General $661 6
2022 General $128 1
2021 General $117 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mustufa Jafry
  • MOHS-Micrographic Surgery median
  • Middle half of MOHS-Micrographic Surgery
  • National median

In program year 2025, general payments to Mustufa Jafry were reported at $1,730. Among 1,077 MOHS-Micrographic Surgery profiles paid that year, the median was $465 and the middle half received between $145 and $1,066.

Show as a table
Year Mustufa Jafry MOHS-Micrographic Surgery median Middle half National median
2019 $0 $316 $106–$785 $163
2020 $0 $162 $68–$412 $114
2021 $117 $243 $87–$654 $132
2022 $128 $300 $102–$887 $149
2023 $661 $364 $125–$1,010 $160
2024 $1,657 $445 $142–$1,108 $164
2025 $1,730 $465 $145–$1,066 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Regeneron Healthcare Solutions, Inc. $497 9 payments
  2. Genzyme Corporation $476 5 payments
  3. Janssen Biotech, Inc. $390 5 payments
  4. Dermavant Sciences, Inc. $383 3 payments
  5. UCB, Inc. $359 5 payments
  6. Amgen Inc. $290 8 payments
  7. Galderma Laboratories, L.P. $242 3 payments
  8. Lilly USA, LLC $219 2 payments
  9. Journey Medical Corporation $203 2 payments
  10. Pfizer Inc. $195 2 payments
  11. Other $1,038 19 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,193 62 payments
  2. Education $100 1 payment
Products named General payments · program years 2021–2025
  1. DUPIXENT Immunology $588 6 payments
  2. TREMFYA $390 5 payments
  3. VTAMA $383 3 payments
  4. Bimzelx $359 5 payments
  5. Otezla $290 8 payments
  6. DUPIXENT Inflammation And Immunology $210 2 payments
  7. DUPIXENT Immunology And Inflammation $207 3 payments
  8. ILUMYA $149 2 payments
  9. INNOVAMATRIX AC $140 1 payment
  10. SKYRIZI $133 5 payments
  11. Other $1,237 21 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

222

Median for Dermatology: 534

Drug cost

$69,283

Median for Dermatology: $67,151

Branded share of claims

8.1%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 18 $65,008
Tacrolimus Generic 12 $894
Clindamycin Phosphate Generic 19 $843
Ketoconazole Generic 51 $837
Triamcinolone Acetonide Generic 59 $593
Doxycycline Hyclate Generic 12 $523
Clobetasol Propionate Generic 14 $299
Hydrocortisone Generic 37 $286

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VTAMA
  • Dermavant Sciences, Inc. $383
$383 — —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $210
  • GENZYME CORPORATION $99
$309 18 —
LITFULO
  • PFIZER INC. $125
$125 — —
ILUMYA
  • Sun Pharmaceutical Industries Inc. $121
$121 — —
Otezla
  • Amgen Inc. $109
$109 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

63 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other MOHS-Micrographic Surgery in Washington

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record